ArticleCurrent treatment options in cardiovascular medicine2013
Optimal strategies including use of newer anticoagulants for prevention of stroke and bleeding complications before, during, and after catheter ablation of atrial fibrillation and atrial flutter.
Article in Current treatment options in cardiovascular medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Safetyof Dabigatran Versus Warfarin in Patients Undergoing Atrial Fibrillation Ablation.Journal of atrial fibrillationArticle
- Post-Procedural Dabigatran Versus Interrupted Warfarin Therapy Following Catheter Ablation for Atrial Fibrillation.Journal of atrial fibrillationArticle
- My Patient Taking A Novel Oral Anticoagulant Needs Surgery, Device Implantation, Or Ablation.Journal of atrial fibrillationReview
- Comparison of peri-procedural anticoagulation with rivaroxaban and apixaban during radiofrequency ablation of atrial fibrillation.Indian pacing and electrophysiology journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementAnticoagulation is a key component of peri-procedural care for patients undergoing catheter ablation for atrial fibrillation (AF) and atrial flutter (AFL). The timing of discontinuation and re-initiation of anticoagulants in the peri-procedural time frame is an important consideration in trying to minimize the risk of stroke and procedure-related bleeding. Until recently, options for oral anticoagulation were limited to warfarin, which typically requires 4-5 days before a therapeutic International Normalized Ratio (INR) is achieved. Therefore, patients deemed to have a high risk of peri-procedural stroke had to either have their procedure performed with a therapeutic INR, or with cessation of warfarin and the adjunctive use of bridging heparinoids. Recently, however, three novel oral anticoagulant agents, each with a rapid onset of action, have been approved by the FDA for use in thromboembolism prophylaxis in patients with AF and AFL. These new drugs (dabigatran, rivaroxaban, and apixaban) broaden the menu of options with regard to peri-procedural anticoagulation strategies that can be employed for ablation of AF and AFL.
Identifiers
23568665What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.